Skip to main content
Top
Published in: Cardiovascular Diabetology 1/2010

Open Access 01-12-2010 | Original investigation

Fibrinogen and associated risk factors in a high-risk population: urban indigenous australians, the druid Study

Authors: Louise J Maple-Brown, Joan Cunningham, Nirjhar Nandi, Allison Hodge, Kerin O'Dea

Published in: Cardiovascular Diabetology | Issue 1/2010

Login to get access

Abstract

Background

Epidemiological evidence suggests that fibrinogen and CRP are associated with coronary heart disease risk. High CRP in Indigenous Australians has been reported in previous studies including our 'Diabetes and Related diseases in Urban Indigenous population in Darwin region' (DRUID) Study. We studied levels of fibrinogen and its cross-sectional relationship with traditional and non-traditional cardiovascular risk factors in an urban Indigenous Australian cohort.

Methods

Fibrinogen data were available from 287 males and 628 females (aged ≥ 15 years) from the DRUID study. Analysis was performed for associations with the following risk factors: diabetes, HbA1c, age, BMI, waist circumference, waist-hip ratio, total cholesterol, triglyceride, HDL cholesterol, C-reactive protein, homocysteine, blood pressure, heart rate, urine ACR, smoking status, alcohol abstinence.

Results

Fibrinogen generally increased with age in both genders; levels by age group were higher than those previously reported in other populations, including Native Americans. Fibrinogen was higher in those with than without diabetes (4.24 vs 3.56 g/L, p < 0.001). After adjusting for age and sex, the following were significantly associated with fibrinogen: BMI, waist, waist-hip ratio, systolic blood pressure, heart rate, fasting triglycerides, HDL cholesterol, HbA1c, CRP, ACR and alcohol abstinence. On multivariate regression (age and sex-adjusted) CRP and HbA1c were significant independent predictors of fibrinogen, explaining 27% of its variance; CRP alone explained 25% of fibrinogen variance. On factor analysis, both CRP and fibrinogen clustered with obesity in women (this factor explained 20% of variance); but in men, CRP clustered with obesity (factor explained 18% of variance) whilst fibrinogen clustered with HbA1c and urine ACR (factor explained 13% of variance).

Conclusions

Fibrinogen is associated with traditional and non-traditional cardiovascular risk factors in this urban Indigenous cohort and may be a useful biomarker of CVD in this high-risk population. The apparent different associations of fibrinogen with cardiovascular disease risk markers in men and women should be explored further.
Appendix
Available only for authorised users
Literature
1.
go back to reference Heart, stroke and vascular disease: Australian facts 2004. Cardiovascular Disease Series, No. 22. 2004, Canberra: Australian Institute of Health and Welfare and National Heart Foundation of Australia Heart, stroke and vascular disease: Australian facts 2004. Cardiovascular Disease Series, No. 22. 2004, Canberra: Australian Institute of Health and Welfare and National Heart Foundation of Australia
2.
go back to reference Danesh J, Lewington S, Thompson SG, Lowe GD, Collins R, Kostis JB, Wilson AC, Folsom AR, Wu K, Benderly M, et al: Plasma fibrinogen level and the risk of major cardiovascular diseases and nonvascular mortality: an individual participant meta-analysis. JAMA. 2005, 294 (14): 1799-1809. 10.1001/jama.294.14.1799.PubMed Danesh J, Lewington S, Thompson SG, Lowe GD, Collins R, Kostis JB, Wilson AC, Folsom AR, Wu K, Benderly M, et al: Plasma fibrinogen level and the risk of major cardiovascular diseases and nonvascular mortality: an individual participant meta-analysis. JAMA. 2005, 294 (14): 1799-1809. 10.1001/jama.294.14.1799.PubMed
3.
go back to reference Kaptoge S, White IR, Thompson SG, Wood AM, Lewington S, Lowe GD, Danesh J: Associations of plasma fibrinogen levels with established cardiovascular disease risk factors, inflammatory markers, and other characteristics: individual participant meta-analysis of 154,211 adults in 31 prospective studies: the fibrinogen studies collaboration. Am J Epidemiol. 2007, 166 (8): 867-879. 10.1093/aje/kwm191.CrossRefPubMed Kaptoge S, White IR, Thompson SG, Wood AM, Lewington S, Lowe GD, Danesh J: Associations of plasma fibrinogen levels with established cardiovascular disease risk factors, inflammatory markers, and other characteristics: individual participant meta-analysis of 154,211 adults in 31 prospective studies: the fibrinogen studies collaboration. Am J Epidemiol. 2007, 166 (8): 867-879. 10.1093/aje/kwm191.CrossRefPubMed
4.
go back to reference Sakakibara H, Fujii C, Naito M: Plasma fibrinogen and its association with cardiovascular risk factors in apparently healthy Japanese subjects. Heart Vessels. 2004, 19 (3): 144-148. 10.1007/s00380-003-0753-5.CrossRefPubMed Sakakibara H, Fujii C, Naito M: Plasma fibrinogen and its association with cardiovascular risk factors in apparently healthy Japanese subjects. Heart Vessels. 2004, 19 (3): 144-148. 10.1007/s00380-003-0753-5.CrossRefPubMed
5.
go back to reference Stec JJ, Silbershatz H, Tofler GH, Matheney TH, Sutherland P, Lipinska I, Massaro JM, Wilson PF, Muller JE, D'Agostino RB: Association of fibrinogen with cardiovascular risk factors and cardiovascular disease in the Framingham Offspring Population. Circulation. 2000, 102 (14): 1634-1638.CrossRefPubMed Stec JJ, Silbershatz H, Tofler GH, Matheney TH, Sutherland P, Lipinska I, Massaro JM, Wilson PF, Muller JE, D'Agostino RB: Association of fibrinogen with cardiovascular risk factors and cardiovascular disease in the Framingham Offspring Population. Circulation. 2000, 102 (14): 1634-1638.CrossRefPubMed
6.
go back to reference Palmieri V, Celentano A, Roman MJ, de Simone G, Best L, Lewis MR, Robbins DC, Fabsitz RR, Howard BV, Devereux RB: Relation of fibrinogen to cardiovascular events is independent of preclinical cardiovascular disease: the Strong Heart Study. Am Heart J. 2003, 145 (3): 467-474. 10.1067/mhj.2003.144.CrossRefPubMed Palmieri V, Celentano A, Roman MJ, de Simone G, Best L, Lewis MR, Robbins DC, Fabsitz RR, Howard BV, Devereux RB: Relation of fibrinogen to cardiovascular events is independent of preclinical cardiovascular disease: the Strong Heart Study. Am Heart J. 2003, 145 (3): 467-474. 10.1067/mhj.2003.144.CrossRefPubMed
7.
go back to reference Yan RT, Fernandes V, Yan AT, Cushman M, Redheuil A, Tracy R, Vogel-Claussen J, Bahrami H, Nasir K, Bluemke DA, et al: Fibrinogen and left ventricular myocardial systolic function: The Multi-Ethnic Study of Atherosclerosis (MESA). Am Heart J. 2010, 160 (3): 479-486. 10.1016/j.ahj.2010.06.001.PubMedCentralCrossRefPubMed Yan RT, Fernandes V, Yan AT, Cushman M, Redheuil A, Tracy R, Vogel-Claussen J, Bahrami H, Nasir K, Bluemke DA, et al: Fibrinogen and left ventricular myocardial systolic function: The Multi-Ethnic Study of Atherosclerosis (MESA). Am Heart J. 2010, 160 (3): 479-486. 10.1016/j.ahj.2010.06.001.PubMedCentralCrossRefPubMed
8.
go back to reference Gupta AK, Cornelissen G, Greenway FL, Dhoopati V, Halberg F, Johnson WD: Abnormalities in circadian blood pressure variability and endothelial function: pragmatic markers for adverse cardiometabolic profiles in asymptomatic obese adults. Cardiovasc Diabetol. 2010, 9 (1): 58-10.1186/1475-2840-9-58.PubMedCentralCrossRefPubMed Gupta AK, Cornelissen G, Greenway FL, Dhoopati V, Halberg F, Johnson WD: Abnormalities in circadian blood pressure variability and endothelial function: pragmatic markers for adverse cardiometabolic profiles in asymptomatic obese adults. Cardiovasc Diabetol. 2010, 9 (1): 58-10.1186/1475-2840-9-58.PubMedCentralCrossRefPubMed
9.
go back to reference Brunner E, Davey Smith G, Marmot M, Canner R, Beksinska M, O'Brien J: Childhood social circumstances and psychosocial and behavioural factors as determinants of plasma fibrinogen. Lancet. 1996, 347 (9007): 1008-1013. 10.1016/S0140-6736(96)90147-6.CrossRefPubMed Brunner E, Davey Smith G, Marmot M, Canner R, Beksinska M, O'Brien J: Childhood social circumstances and psychosocial and behavioural factors as determinants of plasma fibrinogen. Lancet. 1996, 347 (9007): 1008-1013. 10.1016/S0140-6736(96)90147-6.CrossRefPubMed
10.
go back to reference Wang Z, Rowley K, Best J, McDermott R, Taylor M, O'Dea K: Hemostatic factors in Australian Aboriginal and Torres Strait Islander populations. Metabolism. 2007, 56 (5): 629-635. 10.1016/j.metabol.2006.12.009.CrossRefPubMed Wang Z, Rowley K, Best J, McDermott R, Taylor M, O'Dea K: Hemostatic factors in Australian Aboriginal and Torres Strait Islander populations. Metabolism. 2007, 56 (5): 629-635. 10.1016/j.metabol.2006.12.009.CrossRefPubMed
11.
go back to reference Anand SS, Yusuf S, Jacobs R, Davis AD, Yi Q, Gerstein H, Montague PA, Lonn E: Risk factors, atherosclerosis, and cardiovascular disease among Aboriginal people in Canada: the Study of Health Assessment and Risk Evaluation in Aboriginal Peoples (SHARE-AP). The Lancet. 2001, 358 (9288): 1147-1153. 10.1016/S0140-6736(01)06255-9.CrossRef Anand SS, Yusuf S, Jacobs R, Davis AD, Yi Q, Gerstein H, Montague PA, Lonn E: Risk factors, atherosclerosis, and cardiovascular disease among Aboriginal people in Canada: the Study of Health Assessment and Risk Evaluation in Aboriginal Peoples (SHARE-AP). The Lancet. 2001, 358 (9288): 1147-1153. 10.1016/S0140-6736(01)06255-9.CrossRef
12.
go back to reference Kizer JR, Krauser DG, Rodeheffer RJ, Burnett JC, Okin PM, Roman MJ, Umans JG, Best LG, Lee ET, Devereux RB: Prognostic value of multiple biomarkers in American Indians free of clinically overt cardiovascular disease (from the Strong Heart Study). Am J Cardiol. 2009, 104 (2): 247-253. 10.1016/j.amjcard.2009.03.026.PubMedCentralCrossRefPubMed Kizer JR, Krauser DG, Rodeheffer RJ, Burnett JC, Okin PM, Roman MJ, Umans JG, Best LG, Lee ET, Devereux RB: Prognostic value of multiple biomarkers in American Indians free of clinically overt cardiovascular disease (from the Strong Heart Study). Am J Cardiol. 2009, 104 (2): 247-253. 10.1016/j.amjcard.2009.03.026.PubMedCentralCrossRefPubMed
13.
go back to reference ABS & AIHW (Australian Bureau of Statistics & Australian Institute of Health and Welfare). The Health and Welfare of Australia's Aboriginal and Torres Strait Islander Peoples. 2005, Canberra ABS & AIHW (Australian Bureau of Statistics & Australian Institute of Health and Welfare). The Health and Welfare of Australia's Aboriginal and Torres Strait Islander Peoples. 2005, Canberra
14.
go back to reference Australian Bureau of Statistics. Population Distribution, Indigenous Australians. ABS cat. no. 4705.0. 2002, Canberra Australian Bureau of Statistics. Population Distribution, Indigenous Australians. ABS cat. no. 4705.0. 2002, Canberra
15.
go back to reference Cunningham J, O'Dea K, Dunbar T, Weeramanthri TS, Zimmet P, Shaw J: Study Protocol - Diabetes and related conditions in urban Indigenous people in the Darwin, Australia region: aims, methods and participation in the DRUID Study. BMC Public Health. 2006, 6: 8-10.1186/1471-2458-6-8.PubMedCentralCrossRefPubMed Cunningham J, O'Dea K, Dunbar T, Weeramanthri TS, Zimmet P, Shaw J: Study Protocol - Diabetes and related conditions in urban Indigenous people in the Darwin, Australia region: aims, methods and participation in the DRUID Study. BMC Public Health. 2006, 6: 8-10.1186/1471-2458-6-8.PubMedCentralCrossRefPubMed
16.
go back to reference O'Dea K, Cunningham J, Maple-Brown L, Weeramanthri T, Shaw J, Dunbar T, Zimmet P: Diabetes and cardiovascular risk factors in urban Indigenous adults: Results from the DRUID study. Diabetes Res Clin Pract. 2008, 80 (3): 483-489. 10.1016/j.diabres.2008.02.008.CrossRefPubMed O'Dea K, Cunningham J, Maple-Brown L, Weeramanthri T, Shaw J, Dunbar T, Zimmet P: Diabetes and cardiovascular risk factors in urban Indigenous adults: Results from the DRUID study. Diabetes Res Clin Pract. 2008, 80 (3): 483-489. 10.1016/j.diabres.2008.02.008.CrossRefPubMed
17.
go back to reference World Health Organisation. Definition, Diagnosis and Classification of Diabetes Mellitus and Its Complications. 1999, Geneva: Department of Noncommunicable Disease Surveillance, WHO World Health Organisation. Definition, Diagnosis and Classification of Diabetes Mellitus and Its Complications. 1999, Geneva: Department of Noncommunicable Disease Surveillance, WHO
18.
go back to reference Woodward M, Rumley A, Lowe GD, Tunstall-Pedoe H: C-reactive protein: associations with haematological variables, cardiovascular risk factors and prevalent cardiovascular disease. Br J Haematol. 2003, 122 (1): 135-141. 10.1046/j.1365-2141.2003.04387.x.CrossRefPubMed Woodward M, Rumley A, Lowe GD, Tunstall-Pedoe H: C-reactive protein: associations with haematological variables, cardiovascular risk factors and prevalent cardiovascular disease. Br J Haematol. 2003, 122 (1): 135-141. 10.1046/j.1365-2141.2003.04387.x.CrossRefPubMed
19.
go back to reference Kaptoge S, Di Angelantonio E, Lowe G, Pepys MB, Thompson SG, Collins R, Danesh J: C-reactive protein concentration and risk of coronary heart disease, stroke, and mortality: an individual participant meta-analysis. Lancet. 2010, 375 (9709): 132-140. 10.1016/S0140-6736(09)61717-7.CrossRefPubMed Kaptoge S, Di Angelantonio E, Lowe G, Pepys MB, Thompson SG, Collins R, Danesh J: C-reactive protein concentration and risk of coronary heart disease, stroke, and mortality: an individual participant meta-analysis. Lancet. 2010, 375 (9709): 132-140. 10.1016/S0140-6736(09)61717-7.CrossRefPubMed
20.
go back to reference Jax TW, Peters AJ, Plehn G, Schoebel FC: Hemostatic risk factors in patients with coronary artery disease and type 2 diabetes - a two year follow-up of 243 patients. Cardiovasc Diabetol. 2009, 8: 48-10.1186/1475-2840-8-48.PubMedCentralCrossRefPubMed Jax TW, Peters AJ, Plehn G, Schoebel FC: Hemostatic risk factors in patients with coronary artery disease and type 2 diabetes - a two year follow-up of 243 patients. Cardiovasc Diabetol. 2009, 8: 48-10.1186/1475-2840-8-48.PubMedCentralCrossRefPubMed
21.
go back to reference Shemesh T, Rowley KG, Jenkins A, Brimblecombe J, Best JD, O'Dea K: Differential association of C-reactive protein with adiposity in men and women in an Aboriginal community in northeast Arnhem Land of Australia. 2006, 31 (1): 103-108. Shemesh T, Rowley KG, Jenkins A, Brimblecombe J, Best JD, O'Dea K: Differential association of C-reactive protein with adiposity in men and women in an Aboriginal community in northeast Arnhem Land of Australia. 2006, 31 (1): 103-108.
22.
go back to reference Hanley AJ, Festa A, D'Agostino RB, Wagenknecht LE, Savage PJ, Tracy RP, Saad MF, Haffner SM: Metabolic and inflammation variable clusters and prediction of type 2 diabetes: factor analysis using directly measured insulin sensitivity. Diabetes. 2004, 53 (7): 1773-1781. 10.2337/diabetes.53.7.1773.CrossRefPubMed Hanley AJ, Festa A, D'Agostino RB, Wagenknecht LE, Savage PJ, Tracy RP, Saad MF, Haffner SM: Metabolic and inflammation variable clusters and prediction of type 2 diabetes: factor analysis using directly measured insulin sensitivity. Diabetes. 2004, 53 (7): 1773-1781. 10.2337/diabetes.53.7.1773.CrossRefPubMed
23.
go back to reference Sakkinen PA, Wahl P, Cushman M, Lewis MR, Tracy RP: Clustering of procoagulation, inflammation, and fibrinolysis variables with metabolic factors in insulin resistance syndrome. Am J Epidemiol. 2000, 152 (10): 897-907. 10.1093/aje/152.10.897.CrossRefPubMed Sakkinen PA, Wahl P, Cushman M, Lewis MR, Tracy RP: Clustering of procoagulation, inflammation, and fibrinolysis variables with metabolic factors in insulin resistance syndrome. Am J Epidemiol. 2000, 152 (10): 897-907. 10.1093/aje/152.10.897.CrossRefPubMed
Metadata
Title
Fibrinogen and associated risk factors in a high-risk population: urban indigenous australians, the druid Study
Authors
Louise J Maple-Brown
Joan Cunningham
Nirjhar Nandi
Allison Hodge
Kerin O'Dea
Publication date
01-12-2010
Publisher
BioMed Central
Published in
Cardiovascular Diabetology / Issue 1/2010
Electronic ISSN: 1475-2840
DOI
https://doi.org/10.1186/1475-2840-9-69

Other articles of this Issue 1/2010

Cardiovascular Diabetology 1/2010 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.